The Center for Inquiry weighs in on the FDA’s mishandling of Stanislaw Burzynski’s clinical trials

If you’ve ever wondered whether a government agency can both be the adult in the room and the one who “accidentally” leaves the door unlocked,
welcome to one of the messiest intersections of medicine, regulation, politics, and human desperation.
In 2014, the Center for Inquiry (CFI) publicly argued that the U.S. Food and Drug Administration (FDA) mishandled clinical trials tied to Dr. Stanislaw Burzynski,
a Houston physician known for promoting “antineoplastons,” an unapproved cancer treatment offered through clinical trials at his clinic.

This story isn’t just about one doctor or one agency. It’s about the promises and guardrails of clinical research:
informed consent that actually informs, protocols that actually get followed, and oversight strong enough to protect patients who are already dealing with the one thing nobody asked forcancer.
And yes, there’s also politics, fundraising, and enough paperwork to deforest a small country. (Kidding. Mostly.)

First, the cast: CFI, the FDA, and the Burzynski controversy

The FDA regulates drugs in the United States and is supposed to ensure that medical decisions can be grounded in sound evidence and truthful information.
That’s the theory. In practice, the FDA has to juggle scientific review, legal constraints, limited resources, and public pressuresometimes all before lunch.

The Center for Inquiry (CFI) is an advocacy organization that focuses on promoting reason, science, and evidence-based thinking.
In the Burzynski saga, CFI framed the issue as consumer protection: patients shouldn’t be exploited by pseudoscientific claims that borrow the prestige of “clinical trials” without meeting the responsibilities clinical trials demand.

Dr. Stanislaw Burzynski has promoted antineoplastons for decades.
The National Cancer Institute (NCI) notes that antineoplastons are not FDA-approved for preventing or treating any disease,
and that the evidence supporting them as cancer treatment has been considered inconclusive, with calls for controlled clinical trials to assess their value.
Yet patients have continued to seek the therapy, often as a last resort.

What CFI actually said: “This is the FDA’s jobprotect patients from exploitation”

In a 2014 blog post, CFI President Ronald A. Lindsay argued that Burzynski’s long-running promotion of an unproven cancer therapy, combined with steep patient costs,
created a perfect storm for exploitation. His core point was blunt: desperate patients shouldn’t be expected to personally validate a treatment’s claims,
and they shouldn’t have to reverse-engineer regulatory compliance while trying to stay alive.

CFI’s critique wasn’t “the FDA never did anything.” It was closer to: “The FDA did thingsinspections, warnings, holdsbut then reversed course at key moments in ways that undermined protection.”
Lindsay suggested the reversal may have been driven by political pressure, arguing that letting Burzynski continue under expanded access (“compassionate use”) and allowing trials to restart
looked like an abdication of responsibility, because it allowed a disputed therapy to wear the lab coat of legitimacy without clearing the evidence bar.

That framing matters. “Clinical trial” can sound like a stamp of quality to regular people.
But in real research ethics, a clinical trial is not a vibes-based permission slipit’s a tightly governed process with rules designed to protect human beings from being turned into expensive experiments.

The FDA paper trail: why “procedural” problems are not paperwork trivia

One reason the Burzynski case keeps resurfacing is that the FDA’s own documents raised concerns about how trials were conducted and how risks were handled.
A 2013 FDA Form 483 (inspection observations) for Burzynski as a clinical investigator included observations such as failures to conduct investigations in accordance with the signed investigator statement and the investigational plan,
including protocol-related requirements tied to outcomes and response criteria.
That’s not a clerical issue; it’s the difference between research and improvisation.

Around the same period, reporting summarized an FDA warning letter describing problems such as exaggerating success, inadequate reporting of side effects,
and insufficient precautions to prevent overdose in trial participants.
These are the kinds of failures that can distort results and endanger patientsan especially bad combo when participants are medically vulnerable.

Informed consent isn’t a signatureit’s the “no surprises” contract for reality

Informed consent is supposed to help people understand what’s experimental, what’s known, what’s unknown, and what risks and costs might come with participation.
U.S. regulations explicitly include disclosing any additional costs to subjects that may result from participation.
That’s not optional: it exists because financial pressure can become a form of coercion, especially in life-or-death scenarios.

FDA correspondence tied to Burzynski’s trials flagged informed consent issues, including concerns about missing required disclosures and the timing and content of financial agreements.
Whether you’re a patient, caregiver, or just someone who likes the idea of “ethics,” this is a flashing red sign:
if trial participation comes with unclear or shifting financial obligations, the consent process is not doing its job.

Clinical holds: the regulatory pause button that everyone argues about

The FDA can place a clinical holda delay or suspension of clinical investigationswhen there are safety concerns or other serious compliance problems.
Holds can be partial (for example, stopping new enrollment in certain populations) or broader.
In the public imagination, a hold can look like “the FDA is blocking hope.”
In the ethics reality, a hold can mean “the safety system is workingat least for a moment.”

Public reporting and corporate filings describe a partial clinical hold related to a Burzynski-affiliated study being removed on June 20, 2014.
Critics, including CFI-aligned voices, pointed to the lift as baffling given the history of compliance concerns.
Supporters saw it as vindication. The FDA, constrained by confidentiality rules around investigational drugs, offered limited public detailfueling frustration on all sides.

Why the FDA can look slow, silent, or inconsistent (and why that still doesn’t settle the moral question)

One of the most underrated villains in this story is confidentiality.
Investigational New Drug (IND) information is tightly protected. Even Freedom of Information Act (FOIA) requests can hit walls when they seek details about an experimental product.
Investigative reporting has described how difficult it can be to obtain the underlying documents that explain why the FDA actedor didn’tespecially in real time.

Then there’s political pressure.
Reporting has described lawmakers writing to the FDA about Burzynskisometimes urging the agency to grant compassionate use exemptions or allow trials to proceed,
and sometimes urging crackdown. That’s a problem because agencies can end up forced into performing regulation in a spotlight designed for theater, not nuance.

CFI’s point, however, wasn’t “regulation is easy.” It was “patient protection is non-negotiable.”
If a system is so constrained that it can’t stop exploitation, the system needs fixingnot excuses.

The evidence question: “Where are the randomized, controlled trials?”

If you want to understand why the Burzynski debate never dies, focus on one stubborn fact pattern:
the evidence base has not convinced major scientific and medical institutions that antineoplastons are an effective, proven cancer therapy.
The NCI’s PDQ summary notes that published reports include case reports and early-phase studies, often authored by the therapy’s developer and associates,
and that other investigators have not successfully duplicated the reported results. The NCI states the evidence is inconclusive
and that controlled clinical trials are necessary to assess value.

That last phrase“controlled clinical trials”is doing a lot of heavy lifting.
It means not just “patients were treated” but “results were tested in a way that can separate signal from noise, bias, and wishful thinking.”
Without that, you can’t responsibly claim a treatment works, especially when people are paying serious money and potentially foregoing standard care.

Costs, “case management fees,” and the ethics of charging desperate people

Plenty of legitimate clinical trials involve costs to participants (travel, time off work, childcare, co-pays for standard-of-care components).
But in general, patients are not supposed to be purchasing a miracle with a credit card swipe disguised as “research participation.”
That’s why informed consent rules emphasize disclosing costs and why reputable cancer organizations tell patients to ask who pays for what.

In the Burzynski case, critics highlighted that patients could be charged substantial fees even while the therapy remained unapproved.
This is where CFI’s consumer-protection lens bites hardest: when an unproven treatment is sold with the aura of science,
the financial risk becomes part of the harmespecially if the likelihood of benefit is unknown and the marketing leans optimistic.

A useful gut-check is this: in a well-run trial, you should never feel like you’re being “upsold” on hope.
If the financial conversation starts sounding like a car dealership (“What monthly payment would make curing cancer comfortable for you?”),
you’re not in a research environmentyou’re in a sales funnel wearing a lab coat.

Oversight doesn’t stop at the clinic: manufacturing quality and the 2016 warning

Even if you put evidence debates aside (you shouldn’t, but stay with me), there’s another reality:
drugs must be manufactured under conditions that protect patients from contamination, potency problems, and quality failures.
In 2016, an FDA warning letter to Burzynski’s manufacturing facility described significant current good manufacturing practice (CGMP) violations,
including failures tied to preventing microbiological contamination of purportedly sterile drug products and shortcomings in environmental monitoring and aseptic controls.

This matters because vulnerable patientsespecially those with cancercan be immunocompromised.
When manufacturing controls are weak, risk isn’t theoretical. It’s biological. It’s the kind of thing that turns “experimental treatment” into “experimental infection.”
That’s why CGMP exists: not to annoy manufacturers, but to keep the medicine from becoming its own hazard.

So what would “not mishandling” look like?

CFI’s critique implies a higher bar for decisive enforcement when a therapy appears to persist for decades without convincing evidence,
while drawing patients through marketing, fundraising networks, and political intervention.
In practical terms, “not mishandling” would mean:

• Clear, consistent enforcement of trial rulesprotocol compliance, accurate reporting, adverse-event handling, and oversight.
• Stronger guardrails against financial exploitation, including rigorous consent disclosures and scrutiny of payment structures.
• Reducing the optics gap where “FDA-allowed trial” is interpreted publicly as “FDA thinks this works.”
• Transparency where legally possible, so the public isn’t left to fill the silence with conspiracy theories or marketing narratives.

The hard truth is that regulation is often forced to choose between imperfect options:
block access and be accused of cruelty, or allow access and risk enabling harm.
Expanded access (compassionate use) exists for a reason. But expanded access is supposed to be a narrow pathway for extraordinary circumstances,
not a permanent business model for an unproven therapy.

Reader takeaway: a quick “Hope, but verify” checklist

If you ever encounter a treatment that sounds too good to be true (especially one surrounded by lawsuits, documentaries, fundraising campaigns, or congressional letters),
here are practical questions that cut through the fog:

1. Is it FDA-approved for this use? If not, what evidence supports it?
2. Where are the results published? Are there randomized controlled trials? Independent replication?
3. Is the trial listed on ClinicalTrials.gov? Do the endpoints look meaningful, and are results reported?
4. Who pays for what? Ask for a written breakdown of expected costs and what insurance might cover.
5. Who is overseeing the trial? What IRB is responsible, and what safety monitoring exists?
6. What are the realistic outcomes? A legitimate team will discuss uncertainty without getting offended.
7. Is anyone pressuring you to decide fast? Urgency can be real in cancer carebut sales urgency is a different creature.

Real-World Experiences: what people often live through in cases like this (and what it teaches)

Now for the human partthe piece that doesn’t fit neatly into a regulatory memo.
When controversial, unproven therapies become public causes, the experience for patients and families can feel like being dropped into a choose-your-own-adventure book
where every page is labeled “This could be your last chance.”
People don’t walk into these situations because they love experimental science. They walk in because fear is loud, time is short,
and hope is one of the only emotions that doesn’t make you want to scream into a pillow.

One common experience is the information whiplash.
Families might hear “miracle” stories in online groups, then hear skepticism from oncologists, then see regulatory action (like a hold or a warning letter),
and then watch that action apparently reverse. The emotional translation goes something like:
“If the FDA is stopping it, maybe it’s dangerous… but if the FDA is allowing it again, maybe it works… unless the FDA is corrupt… unless the doctor is a genius… unless everyone is lying.”
A person can develop a full-time job just trying to interpret what the adults are doing.

Another recurring experience is fundraising pressure.
When a treatment is expensive and insurance won’t cover it (or coverage is unclear), families turn to communities.
That can be inspiringhumans can be unbelievably generousbut it can also be psychologically brutal.
People feel like they must be persuasive 24/7: posting updates, sharing scans, staying upbeat, and thanking donors while privately panicking.
The treatment becomes not just medical care but a public campaign, and “being sick” becomes a performance with a donation button.

There’s also the experience of advocacy-by-necessity.
Some patients learn about “expanded access” and “compassionate use” because they have to.
They become mini policy analysts overnightcalling offices, collecting signatures, emailing lawmakers, and trying to speak “FDA” fluently.
The irony is that the FDA itself warns that investigational products may or may not work and can cause serious side effects, but when you’re staring at grim odds,
“may or may not” can sound like “worth a shot,” especially if someone else is selling it as certainty.

People also describe relationship strain.
In families, disagreements can erupt: one person wants standard-of-care, another wants “anything, no matter what,” another is worried about finances,
and someone else is deep in internet rabbit holes at 2 a.m. None of these people are villains. They are people trying to regain control.
But when hope is packaged as a product, it can wedge itself between loved ones like a crowbar.

Finally, many people come away with a new appreciation for what real clinical research is supposed to feel like.
In a high-quality research setting, the team does not sell you optimism. They explain uncertainty.
They talk about risks without acting like you’re being negative.
They treat informed consent like a conversation, not a waiver.
And they never make you feel like you’re buying entry into a miracle story.
If your “trial experience” feels like a subscription serviceespecially one that gets pricier the more scared you arethat’s not innovation.
That’s a warning sign with a nicer font.

The Burzynski story, and CFI’s frustration with the FDA’s approach, reflects a larger lesson:
patient protection is not only about stopping bad actors; it’s also about making the trustworthy path easier to recognize.
When oversight looks inconsistent, patients don’t just lose faith in one agencythey lose faith in the idea that science can protect them at all.
And that loss is expensive in ways no invoice can capture.

Conclusion: why this debate still matters

CFI’s argument about the FDA’s mishandling of Burzynski’s clinical trials is ultimately an argument about what regulation is for.
It’s not to crush hope. It’s to make sure hope doesn’t get weaponized against people who are already vulnerable.
Clinical trials are supposed to create reliable knowledge while protecting participantsnot provide a scientific costume for long-running, unproven treatments.

If there’s a bottom line here, it’s this: in cancer care, “try everything” is an understandable feeling.
But “try everything” should never become “pay anything for anything.”
The job of oversightand the reason CFI spoke upis to make sure the difference is visible before families pay in money, time, and trust.